AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15234277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline, 30 mg three times daily
Number of subjects: 60
Study 15234277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11529977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum feeding regimen
Number of subjects: 100
Study 11529977 — intervention group
Group type: COMPARATOR
Intervention: Prescribed feeding regimen
Number of subjects: 100
Study 9763788 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase contrast gradient-echo after gadolinium injection
Number of subjects: 10
Study 9763788 — intervention group
Group type: EXPERIMENTAL
Intervention: TurboSTIR
Number of subjects: 10
Study 9763788 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTEC-Chopper
Number of subjects: 10
Study 8080512 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intensity (400 mg cyclophosphamide, 40 mg doxorubicin, 400 mg fluorouracil for six cycles)
Number of subjects: 1572
Study 8080512 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose intensity (600 mg cyclophosphamide, 60 mg doxorubicin, 600 mg fluorouracil for four cycles)
Number of subjects: 1572
Study 8080512 — intervention group
Group type: COMPARATOR
Intervention: Low dose intensity (half the total dose of the other two groups)
Number of subjects: 1572
Study 2140372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 103
Study 2140372 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 103
Study 7433897 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone, 150 mg/daily
Number of subjects: 0
Study 7433897 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 400 mg at bedtime
Number of subjects: 0
Study 30367939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d)
Number of subjects: 54
Study 30367939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 30367939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d) in individuals with greater vitamin D deficiency (25(OH)D < 30 nmol/L)
Number of subjects: 54
Study 28686982 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with pelvic floor muscle exercise and lifestyle advice
Number of subjects: 40
Study 28686982 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving lifestyle advice and pelvic floor muscle exercise without biofeedback
Number of subjects: 40
Study 25946376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative print plus telephone intervention at 12 months
Number of subjects: 1280
Study 25946376 — intervention group
Group type: EXPERIMENTAL
Intervention: Print intervention alone at 6 months
Number of subjects: 1280
Study 25946376 — intervention group
Group type: COMPARATOR
Intervention: Cumulative interventions vs print intervention alone
Number of subjects: 1280
Study 25946376 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness of intervention among ethnic subgroups
Number of subjects: 1280
Study 24001701 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 232
Study 24001701 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 232
Study 21183747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure
Number of subjects: 0
Study 21183747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean arterial pressure
Number of subjects: 0
Study 21183747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pulse pressure
Number of subjects: 0
Study 21183747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blood pressure variability
Number of subjects: 0
Study 21183747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blood pressure parameters
Number of subjects: 0
Study 18644685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks
Number of subjects: 113
Study 18644685 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus placebo sertraline
Number of subjects: 113
Study 18644685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with sertraline
Number of subjects: 113
Study 18644685 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone with placebo
Number of subjects: 113
Study 17875198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + proton pump inhibitor
Number of subjects: 30
Study 17875198 — intervention group
Group type: COMPARATOR
Intervention: Doubling the proton pump inhibitor dose
Number of subjects: 30
Study 14734123 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan (mean dose 144 +/- 125 mg/day, dosages of 30 mg, 100 mg, or 300 mg for 3 weeks)
Number of subjects: 31
Study 14734123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11452711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 14
Study 11452711 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 14
Study 9756581 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supervised, 8-week, 3-times-per-week, home-based exercise program
Number of subjects: 20
Study 9756581 — intervention group
Group type: COMPARATOR
Intervention: Usual care as prescribed by the patients' physicians
Number of subjects: 20
Study 7809773 — intervention group
Group type: COMPARATOR
Intervention: Detergent, Metsan
Number of subjects: 60
Study 7809773 — intervention group
Group type: COMPARATOR
Intervention: Metsan combined with acaricide, Acarosan
Number of subjects: 60
Study 7809773 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 60
Study 3107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 101
Study 3107600 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 101
Study 3107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 29389738 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 10 mg od
Number of subjects: 59
Study 29389738 — intervention group
Group type: COMPARATOR
Intervention: doxazosin 8 mg od
Number of subjects: 59
Study 27437724 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music therapy (AMT) plus standard of care (SC)
Number of subjects: 30
Study 27437724 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 30
Study 25743829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy
Number of subjects: 460
Study 25743829 — intervention group
Group type: COMPARATOR
Intervention: High-frequency microsatellite instability without adjuvant chemotherapy
Number of subjects: 460
Study 25743829 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 460
Study 25743829 — intervention group
Group type: COMPARATOR
Intervention: High-frequency microsatellite instability
Number of subjects: 460
Study 23246249 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of oral doxycycline (Doxy-7)
Number of subjects: 40
Study 23246249 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of oral doxycycline (Doxy-14)
Number of subjects: 40
Study 23246249 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Doxy-7 and Doxy-14)
Number of subjects: 40
Study 21444113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 600 mg/d)
Number of subjects: 308
Study 21444113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 308
Study 21444113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 18193917 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg twice daily)
Number of subjects: 12
Study 18193917 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg twice daily)
Number of subjects: 12
Study 18193917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Allopurinol + Probenecid)
Number of subjects: 12
Study 16552508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector CT enteroclysis (MDCT‐E)
Number of subjects: 52
Study 16552508 — intervention group
Group type: COMPARATOR
Intervention: Barium enteroclysis with methylcellulose (BE)
Number of subjects: 52
Study 12612033 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 10 ms interval between median nerve stimulation and TMS pulse.
Number of subjects: 0
Study 12612033 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 25 ms interval between median nerve stimulation and TMS pulse.
Number of subjects: 0
Study 12612033 — intervention group
Group type: COMPARATOR
Intervention: PAS(10 ms) under the influence of dextromethorphan (an NMDA receptor antagonist).
Number of subjects: 0
Study 12612033 — intervention group
Group type: COMPARATOR
Intervention: PAS(10 ms) under the influence of nimodipine (an L-type voltage-gated calcium-channel antagonist).
Number of subjects: 0
Study 11028833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg) daily for 28 days
Number of subjects: 30
Study 8649631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) - enoxaparin 40 mg/0.4 ml
Number of subjects: 6
Study 8649631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1335012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and placebo tablets
Number of subjects: 12
Study 1335012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once a day and inactivity
Number of subjects: 12
Study 1335012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and atenolol 50 mg once a day
Number of subjects: 12
Study 6724794 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (7.5 g in a 25% solution before meals)
Number of subjects: 31
Study 6724794 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo, same amount as glycerol)
Number of subjects: 31
Study 31262317 — intervention group
Group type: COMPARATOR
Intervention: Postal follow-up
Number of subjects: 2074
Study 31262317 — intervention group
Group type: COMPARATOR
Intervention: Online follow-up
Number of subjects: 2074
Study 31262317 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up
Number of subjects: 2074
Study 31262317 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face follow-up
Number of subjects: 2074
Study 28582271 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate (CHO) loading (800 mL of water containing 100 g of CHO)
Number of subjects: 880
Study 28582271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (800 mL of water)
Number of subjects: 880
Study 27427996 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 20 U
Number of subjects: 225
Study 24656402 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium (CM) enhanced MRI
Number of subjects: 716
Study 24656402 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium (CM) enhanced CT
Number of subjects: 716
Study 24656402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast)
Number of subjects: 716
Study 22370487 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded workplace depression treatment programs
Number of subjects: 0
Study 22370487 — intervention group
Group type: COMPARATOR
Intervention: Treatment for major depressive disorder (MDD)
Number of subjects: 0
Study 22370487 — intervention group
Group type: COMPARATOR
Intervention: Detection and treatment of depression among patients with chronic physical disorders
Number of subjects: 0
Study 22370487 — intervention group
Group type: COMPARATOR
Intervention: Early MDD treatment interventions
Number of subjects: 0
Study 20852963 — intervention group
Group type: EXPERIMENTAL
Intervention: [¹H]MRSI
Number of subjects: 150
Study 20852963 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 150
Study 20852963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of [¹H]MRSI and DCE-MRI
Number of subjects: 150
Study 17656179 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education and clinic-based counseling promoting use of male and female condoms
Number of subjects: 935
Study 17656179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonuse of effective contraceptives and self-reported unprotected sex
Number of subjects: 935
Study 17656179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes
Number of subjects: 935
Study 15813810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroids (budesonide 400 microg daily)
Number of subjects: 41
Study 15813810 — intervention group
Group type: COMPARATOR
Intervention: Specific allergen immunotherapy (SIT)
Number of subjects: 41
Study 12154417 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution therapy
Number of subjects: 44
Study 12154417 — intervention group
Group type: COMPARATOR
Intervention: OP‐CAB surgery
Number of subjects: 44
Study 10217079 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with CA 125 and ultrasonography
Number of subjects: 21935
Study 10217079 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 21935
Study 10217079 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21935
Study 8682006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 16
Study 8682006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Balke protocol)
Number of subjects: 16
Study 8682006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Bruce and Steep protocols)
Number of subjects: 16
Study 8682006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Ellestad protocol)
Number of subjects: 16
Study 2136113 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer reports of abstinence
Number of subjects: 0
Study 727414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-1.0% halothane
Number of subjects: 28
Study 727414 — intervention group
Group type: COMPARATOR
Intervention: 50 microgram fentanyl/kg
Number of subjects: 28
Study 31245903 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 434
Study 31245903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis surgery
Number of subjects: 434
Study 31245903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet surgery
Number of subjects: 434
Study 27841795 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 0
Study 27841795 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study 26164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid debridement‐scaling (LDS)
Number of subjects: 14
Study 26164314 — intervention group
Group type: COMPARATOR
Intervention: Control (no LDS)
Number of subjects: 14
Study 23835764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 2
Study 23835764 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 2
Study 21673685 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 2034
Study 21673685 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 (5‐fluorouracil/folinic acid plus oxaliplatin)
Number of subjects: 2034
Study 21673685 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX/XELOX‐placebo/XELOX‐bevacizumab arms
Number of subjects: 2034
Study 21673685 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4/FOLFOX4‐placebo/FOLFOX4‐bevacizumab arms
Number of subjects: 2034
Study 21673685 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 2034
Study 21673685 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 2034
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based preventive oral health program
Number of subjects: 1748
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic preventive program
Number of subjects: 1748
Study 19250295 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1748
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote schools
Number of subjects: 1748
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with black stain
Number of subjects: 1748
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Children without black stain
Number of subjects: 1748
Study 19250295 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with and without black stain
Number of subjects: 1748
Study 18162029 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DRSP (ethinyl estradiol 30 mug/day plus drospirenone 3 mg/day)
Number of subjects: 25
Study 18162029 — intervention group
Group type: COMPARATOR
Intervention: EE (ethinyl estradiol 30 mug/day)
Number of subjects: 25
Study 18162029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15358970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 406
Study 15358970 — intervention group
Group type: COMPARATOR
Intervention: Physician
Number of subjects: 406
Study 11800061 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan, 600‐800 mg once daily
Number of subjects: 334
Study 11800061 — intervention group
Group type: COMPARATOR
Intervention: Enalapril, 5‐20 mg once daily
Number of subjects: 334
Study 11800061 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 334
Study 11800061 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 334
Study 9840406 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (HNa), 348.4 mmol x day(‐1), n=7
Number of subjects: 25
Study 9840406 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium intake (MNa), 174.1 mmol x day(‐1), n=9
Number of subjects: 25
Study 9840406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (LNa), 66.3 mmol x day(‐1), n=9
Number of subjects: 25
Study 9840406 — intervention group
Group type: COMPARATOR
Intervention: All conditions (HNa, MNa, LNa)
Number of subjects: 25
Study 8037128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction radiofrequency ablation plus pacemaker therapy (n = 12)
Number of subjects: 23
Study 8037128 — intervention group
Group type: COMPARATOR
Intervention: Pacemaker therapy alone (n = 11)
Number of subjects: 23
Study 8037128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction radiofrequency ablation
Number of subjects: 23
Study 2725928 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 40
Study 2725928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31432080 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsurgical electrical stimulation (PES) following surgery for severe cubital tunnel syndrome, 1 hour of 20 Hz PES after surgery.
Number of subjects: 31
Study 31432080 — intervention group
Group type: COMPARATOR
Intervention: Control group received cubital tunnel surgery and sham stimulation.
Number of subjects: 31
Study 31432080 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsurgical electrical stimulation (PES) following surgery for severe cubital tunnel syndrome.
Number of subjects: 31
Study 30080726 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 108
Study 30080726 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 108
Study 29063853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy plus External Beam Radiation Therapy (EBRT)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone
Number of subjects: 5836
Study 29063853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (favorable intermediate-risk)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone (favorable intermediate-risk)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (unfavorable intermediate-risk)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone (unfavorable intermediate-risk)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (high-risk)
Number of subjects: 5836
Study 29063853 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone (high-risk)
Number of subjects: 5836
Study 25970794 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 102
Study 25970794 — intervention group
Group type: EXPERIMENTAL
Intervention: OrthoMTA
Number of subjects: 102
Study 25970794 — intervention group
Group type: COMPARATOR
Intervention: ProRoot MTA
Number of subjects: 102
Study 23064441 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg TXA immediately before CS
Number of subjects: 174
Study 23064441 — intervention group
Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 174
Study 22192368 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus DES
Number of subjects: 50
Study 22192368 — intervention group
Group type: COMPARATOR
Intervention: everolimus BVS
Number of subjects: 50
Study 19262394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpronation
Number of subjects: 66
Study 19262394 — intervention group
Group type: COMPARATOR
Intervention: Supination-flexion
Number of subjects: 66
Study 17304419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-walled two-stage twin endotracheal tube (UTTS-T-ETT)
Number of subjects: 28
Study 17304419 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT)
Number of subjects: 28
Study 12930275 — intervention group
Group type: EXPERIMENTAL
Intervention: EVCPP with CABG (group I, n = 14)
Number of subjects: 22
Study 12930275 — intervention group
Group type: COMPARATOR
Intervention: CABG only (group II, n = 8)
Number of subjects: 22